A kidney disease drug that was already considered a significant advance is now proving to be far more powerful — and far more widely applicable — than anyone expected. Three major international studies published in The New England Journal of Medicine and presented at the 2026 European Renal Association Congress in Glasgow in June 2026 found that finerenone does not just help people with diabetic kidney disease — it also dramatically slows the progression of kidney disease and reduces the risk of heart failure, cardiovascular death, and overall mortality in patients who do not have diabetes. That finding potentially opens the door to treatment for millions of Americans who currently have limited options.

For Houston — a city that sits in one of the highest chronic kidney disease burden regions in the United States, driven by its large diabetic and hypertensive population — the news from Glasgow is personal. Harris County and the surrounding Houston metropolitan area consistently rank among Texas's highest CKD prevalence regions, with the Texas Department of State Health Services documenting that more than 1 in 7 Texas adults has some stage of CKD, and that Hispanic and Black Texans face disproportionately higher risks. Approximately 850,000 people in the greater Houston area are estimated to be living with some stage of kidney disease — many of them without a diagnosis.

What the New Studies Found — and Why the Results Are So Significant

Finerenone works by blocking a hormone receptor in the kidneys and heart called the mineralocorticoid receptor, which, when overactivated, drives inflammation and scarring in both organs. Earlier trials — the FIDELIO-DKD and FIGARO-DKD studies — had already established that finerenone reduced kidney failure risk and cardiovascular events in patients with type 2 diabetes and CKD. The new FIND-CKD Phase 3 trial, published online June 5, 2026 in the New England Journal of Medicine, extended those findings to non-diabetic CKD patients — a group that has had almost no proven disease-modifying therapy options. The trial showed a 23% relative risk reduction in a kidney-cardiovascular composite outcome — including kidney failure, cardiovascular death, and hospitalizations — compared to placebo.

In plain language: this drug slows down kidney disease and protects the heart at the same time, and it now works not just for the subset of patients whose kidneys were damaged by diabetes, but for people whose kidneys are failing from any number of causes — including high blood pressure, glomerulonephritis, lupus nephritis, and other conditions. Dr. Hiddo Lambers Heerspink, the lead investigator, stated: "The results show that finerenone significantly preserved kidney function and reduced the risk of cardiovascular-kidney outcomes with a consistent effect across prespecified subgroups, supporting a broad applicability in these patients."

Read more

What Houston Patients Should Ask Their Doctors Right Now

Finerenone (brand name: Kerendia) is already FDA-approved for use in patients with CKD and type 2 diabetes. The new non-diabetic indication will require FDA review before it becomes a formal guideline recommendation — but the data is now in the peer-reviewed literature, and nephrologists and cardiologists at major Houston medical centers including UTHealth Houston, Memorial Hermann, and Houston Methodist are expected to begin integrating these findings into clinical conversations immediately.

If you have been told you have chronic kidney disease, high blood pressure, or protein in your urine — and especially if you have a history of heart failure or cardiovascular disease on top of your kidney diagnosis — ask your doctor or nephrologist whether finerenone is appropriate for you. The American Society of Nephrology and the National Kidney Foundation maintain updated treatment guidelines that your provider can reference. Early intervention to slow CKD progression is far more effective than waiting for kidney failure to develop — and finerenone may now represent the best tool available for a much wider group of patients than previously recognized.